Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.
Use of imatinib in the first-line treatment of children and adolescents with chronic myeloid leukaemia (CML) appears highly effective, yielding excellent response with tolerable side effects, according to the results of a single-arm phase III trial.
Use of bosutinib in the treatment of chronic myeloid leukaemia (CML) still proves to be more effective than imatinib, with a higher major molecular response rate, according to the 24-month follow-up data from the phase III BFORE* trial.
Vitamin C may halt the self-renewal of TET methylcytosine dioxygenase 2 (TET2)-deficient haematopoietic cells and suppress leukaemia progression, in addition to rendering the cells more susceptible to poly ADP ribose polymerase (PARP) inhibition, according to a study.
Nilotinib demonstrates potential in the first-line treatment of patients with chronic myeloid leukaemia, yielding sustained deep molecular response in a clinically significant percentage of patients, according to the results of the phase II ENESTfreedom trial. Importantly, nilotinib-treated patients may remain in treatment-free remission for up to 48 weeks after stopping nilotinib.
Individuals given the BCR-ABL1 tyrosine kinase inhibitor (TKI) imatinib as first-line therapy for chronic myeloid leukaemia (CML) had a high overall survival (OS) rate a decade after initiating therapy, according to long-term follow-up of the IRIS* study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Adjuvant treatment with ipilimumab significantly improved overall survival (OS) among patients with resected high-risk melanoma compared with high-dose interferon-α2b (HDI*), according to final results of the North American Intergroup E1609** trial presented at ASCO 2019.
Use of olaparib in the maintenance setting prolongs progression-free survival in patients with a germline BRCA mutation and metastatic pancreatic cancer as compared with placebo, according to the results of the phase III POLO trial.
Neoadjuvant treatment with trastuzumab emtansine (T-DM1) plus pertuzumab led to an elevated risk of 3-year event-free survival (EFS) events in patients with HER2-positive breast cancer, according to a secondary analysis of the KRISTINE* trial presented at ASCO 2019.
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.